Abstract
PEG is used to improve pharmacokinetic properties of biologicals. Concern has been expressed about the toxicological effect and/or fate of the PEG. This paper reviews the available toxicity, metabolism and clearance data of PEG and PEGylated products in order to place such concerns in to appropriate context. The available data demonstrates that PEG itself only shows toxicity at high, parenteral doses and the usual target organ is the kidney as this is the route of excretion for unchanged PEG. A large therapeutic window (approximately 600-fold) exists between the maximum PEG burden from a current biological agent and the doses of PEG associated with human toxicity. Pathological changes which results in no functional deficit, PEG containing vacuoles in cells, have been observed with PEGylated biologicals. There is evidence that these PEG vesicle can resolve with time. In conclusion the doses used clinically for current and many future PEGylated biologicals are low and will result in exposures to PEG significantly lower than that required to elicit PEG toxicity. In all cases the routine regulatory toxicology studies would identify relevant pathology should it occur.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Webster R, Didier E, Harris P, Siegel N, Stadler J, Tilbury L, Smith D (2007) PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35:9–16
Mehvar R (2000) Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Sci 3:125–136
Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–1458
Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459–476
Morpurgo M, Veronese FM (2004) Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol 283:45–70
Fontana A, Spolaore B, Mero A, Veronese FM (2008) Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60:13–28
Veronese FM, Harris JM (2008) Peptide and protein PEGylation III: advances in chemistry and clinical applications. Adv Drug Deliv Rev 60:1–2
Veronese FM, Harris JM (2002) Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 54:453–456
Fruijtier-Polloth C (2005) Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology 214:1–38
Alden CL, Frith CH (1991) Urinary system. In: Haschek WM, Rousseaux CG (eds): Handbook of Toxicology Pathology. Acedemic Press, New York, 339–341
PegIntron EPAR. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Pegintron/024400en6.pdf. (Accessed 07 April 2008)
Polyethylene glycols (Who Food Additives Series 14). Available at: http://www.inchem.org/documents/jecfa/jecmono/vl4jel9.htm. (Accessed 07 April 2008)
Descamps C, Cabrera G, Depierreux M, Deviere J (2000) Acute renal insufficiency after colon cleansing. Endoscopy 32:S11
Erickson TB, Aks SE, Zabaneh R, Reid R (1996) Acute renal toxicity after ingestion of Lava light liquid. Ann Emerg Med 27:781–784
Bruns DE, Herold DA, Rodeheaver GT, Edlich RF (1982) Polyethylene glycol intoxication in burn patients. Burns Incl Therm Inj 9:49–52
Herold DA, Rodeheaver GT, Bellamy WT, Fitton LA, Bruns DE, Edlich RF (1982) Toxicity of topical polyethylene glycol. Toxicol Appl Pharmacol 65:329–335
McCabe W, Jackson G, Hans G (1959) Treatment of chronic pyelonephritis. Arch Intern Med 104:710–719
Laine GA, Hossain SM, Solis RT, Adams SC (1995) Polyethylene glycol nephrotoxicity secondary to prolonged high-dose intravenous lorazepam. Ann Pharmacother 29:1110–1114
Herold DA, Keil K, Bruns DE (1989) Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem Pharmacol 38:73–76
Schaffer C, Critchfield F, Nair J (1950) The absorption and excretion of a liquid polyethylene glycol. J Am Pharm Assoc Sci Ed 39:340–344
Cruzan G, Corley RA, Hard GC, Mertens JJ, McMartin KE, Snellings WM, Gingell R, Deyo JA (2004) Subchronic toxicity of ethylene glycol in Wistar and F-344 rats related to metabolism and clearance of metabolites. Toxicol Sci 81:502–511
Guo C, McMartin KE (2005) The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation. Toxicology 208:347–355
Na DH, Lee KC (2004) Capillary electrophoretic characterization of PEGylated human parathyroid hormone with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem 331:322–328
Dou H, Zhang M, Zhang Y, Yin C (2007) Synthesis and purification of mono-PEGylated insulin. Chem Biol Drug Des 69:132–138
Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, Yohida T (1988) Protein and polymer analyses up to m/z 100,000 by laser ionization time of flight mass spectrometry. Rapid Communications in Mass Spectroscopy 2:151–153
Weaver R, Riley RJ (2006) Identification and reduction of ion suppression effects on pharmacokinetic parameters by polyethylene glycol 400. Rapid Commun Mass Spectrom 20:2559–2564
Hunt DF, Giordani AB, Rhodes G, Herold DA (1982) Mixture analysis by triple-quadrupole mass spectrometry: metabolic profiling of urinary carboxylic acids. Clin Chem 28:2387–2392
Keevil BG, Thornton S (2006) Quantification of urinary oxalate by liquid chromatography-tandem mass spectrometry with online weak anion exchange chromatography. Clin Chem 52:2296–2299
Tsai NM, Cheng TL, Roffler SR (2001) Sensitive measurement of polyethylene glycol-modified proteins. Biotechniques 30:396–402
Wunderlich DA, Macdougall M, Mierz DV, Toth JG, Buckholz TM, Lumb KJ, Vasavada H (2007) Generation and characterization of a monoclonal IgG antibody to polyethylene glycol. Hybridoma (Larchmt) 26:168–172
Chapman AP (2002) PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54:531–545
Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12:195–202
Kellner K, Tessmar J, Milz S, Angele P, Nerlich M, Schulz MB, Blunk T, Gopferich A (2004) PEGylation does not impair insulin efficacy in three-dimensional cartilage culture: an investigation toward biomimetic polymers. Tissue Eng 10:429–440
Pegasys EPAR. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/pegasys/199602en6.pdf. (Accessed 07 April 2008)
Neulasta EPAR. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/neulas-ta/296102en6.pdf. (Accessed 07 April 2008)
Somavert EPAR. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/somavert/486302en6.pdf (Accessed 07 April 2008)
Macugen EPAR. Available from at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/macu-gen/H-620-en6.pdf. (Accessed 07 April 2008)
Bendele A, Seely J, Richey C, Sennello G, Shopp G (1998) Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42:152–157
Young MA, Malavalli A, Winslow N, Vandegriff KD, Winslow RM (2007) Toxicity and hemodynamic effects after single dose administration of MalPEG-hemoglobin (MP4) in rhesus monkeys. Transi Res 149:333–342
Schaer DJ, Schaer CA, Buehler PW, Boykins RA, Schoedon G, Alayash AI, Schaffner A (2006) CD 163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin. Blood 107:373–380
Shum KL, Leon A, Viau AT, Pilon D, Nucci M, Shorr RG (1996) The physiological and histopathological response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-Hb). Artif Cells Blood Substit Immobil Biotechnol 24:655–683
Conover C, Lejeune L, Linberg R, Shum K, Shorr RG (1996) Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Artif Cells Blood Substit Immobil Biotechnol 24:599–611
Viau AT, Abuchowski A, Greenspan S, Davis FF (1986) Safety evaluation of free radical scavengers PEG-catalase and PEG-superoxide dismutase. J Free Radie Biol Med 2:283–288
Modi MW, Fulton JS, Buckmann DK (2000) Clearance of PEGylated (40KDa) interferone alfa-2a (PEGASYS) is primarily hepatic. Hepatology 32:371A
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Webster, R., Elliott, V., Park, B.K., Walker, D., Hankin, M., Taupin, P. (2009). PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_8
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8679-5_8
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8678-8
Online ISBN: 978-3-7643-8679-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)